MEDTRONIC IRELAND VALIANT CAPTIVIA - FF; SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT
|
Back to Search Results |
|
Model Number VAMF2828C150TE |
Device Problem
Adverse Event Without Identified Device or Use Problem (2993)
|
Patient Problems
Cardiac Arrest (1762); Hemorrhage/Bleeding (1888); Shock (2072); Perforation of Vessels (2135); Respiratory Arrest (4461)
|
Event Date 03/19/2024 |
Event Type
Death
|
Manufacturer Narrative
|
Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
|
Event Description
|
A valiant captivia stent graft was implanted during the endovascular treatment of a 77mm descending thoracic pseudoaneurysm.It was reported during the index procedure, an avulsion of the left external iliac occurred during retrieval of the delivery system, resulting in hemorrhage and cardiovascular arrest.Hemorrhage control and cardiac massage were carried out during emergency treatment, however despite efforts the patient went into sudden cardiorespiratory arrest and hemorrhagic shock and expired.Per the physician the cause of hemorrhage and cardiac arrest was anatomy related anatomy noting arterial insufficiency stage 4.The cause of death was due to sudden cardio respiratory arrest and hemorrhagic shock.
|
|
Manufacturer Narrative
|
Additional information received: the left external iliac was perforated during removal of the delivery system.Calcification & tortuosity arterial pathology stage 4 contributed to the difficulty removing the delivery system.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
|
Search Alerts/Recalls
|
|
|